Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia (REfLecT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01940198 |
Recruitment Status
:
Completed
First Posted
: September 12, 2013
Last Update Posted
: September 12, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
HIV |
This observational study will aim to determine long term atazanavir experience in HIV-1 infected patients in a primary care setting.
3. OBJECTIVES OF THE STUDY i. Primary objective Long-term (2 years or greater) atazanavir experience in HIV-1 infected patients in a primary care setting through retrospective data collection.
ii. Secondary objectives
- To illustrate long term therapeutic efficacy of atazanavir in ART naïve and experienced HIV-1 infected patients.
- To illustrate long term tolerability to atazanavir in ART naïve and experienced HIV-1 infected patients.
- To identify ART treatment history in ART naïve and experienced HIV-1 infected patients on ATV.
- To identify contraindicated therapy in ART naïve and experienced HIV-1 infected patients on ATV.
Study Type : | Observational |
Actual Enrollment : | 117 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia |
Study Start Date : | April 2010 |
Actual Primary Completion Date : | August 2011 |
Actual Study Completion Date : | September 2012 |

- Proportion of HIV-1 infected participants with atazanavir experience [ Time Frame: 1 year ]Proportion of patients who continue on atazanavir for 2 years or greater from baseline to termination/current.
- Proportion of HIV-1 infected participants with atazanavir experience [ Time Frame: 1 year ]1. Therapeutic efficacy of atazanavir
- Proportion of HIV-1 infected participants with atazanavir experience [ Time Frame: 1 year ]Tolerability to atazanavir
- Proportion of HIV-1 infected participants with atazanavir experience [ Time Frame: 1 year ]ART treatment history
- Proportion of HIV-1 infected participants with atazanavir experience [ Time Frame: 1 year ]contraindicated therapy

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Senior |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Cohort of HIV-1 positive patients attending Holdsworth House Medical Practice who have commenced ATV as a component of ART will be identified from review of current database.
Data will be collected retrospectively from patient electronic medical records for HIV-1 positive patients that have commenced ATV from year 2002 - 2008.
Inclusion Criteria:
- HIV-1 positive
- Have commenced ATV between 2002-2008 (Baseline)
- Follow-up data (clinical and laboratory) available from baseline
Exclusion Criteria:
- Patients not commenced ATV between 2002-2008
- No follow-up data (clinical and laboratory) available from baseline
- Patient 'lost to follow-up' with < 2 years of follow-up data (Clinical and laboratory)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01940198
Australia, New South Wales | |
Holdsworth House Medical Practice | |
Sydney, New South Wales, Australia, 2010 |
Principal Investigator: | Mark Bloch, Dr. | Holdsworth House Medical Practice |
Responsible Party: | Dr. Mark Bloch, Principal Investigator, Holdsworth House Medical Practice |
ClinicalTrials.gov Identifier: | NCT01940198 History of Changes |
Other Study ID Numbers: |
AI424-417 ST |
First Posted: | September 12, 2013 Key Record Dates |
Last Update Posted: | September 12, 2013 |
Last Verified: | September 2013 |
Keywords provided by Dr. Mark Bloch, Holdsworth House Medical Practice:
Atazanavir long-term primary care setting sydney |
Additional relevant MeSH terms:
Atazanavir Sulfate HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |